Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia

被引：2

作者：

De Botton, Stephane ^{[1
]}

Yee, Karen ^{[2
]}

Recher, Christian ^{[3
]}

Wei, Andrew H. ^{[4
]}

Montesinos, Pau ^{[5
]}

Taussig, David ^{[6
]}

Pigneux, Arnaud ^{[7
]}

Braun, Thorsten ^{[8
]}

Curti, Antonio ^{[9
]}

Esteve, Jordi ^{[10
]}

Grove, Carolyn ^{[11
]}

Jonas, Brian A. ^{[12
]}

Khwaja, Asim ^{[13
,14
]}

Legrand, Olivier ^{[15
]}

Peterlin, Pierre ^{[16
]}

Sangerman, Montserrat Arnan ^{[17
]}

Blum, William G. ^{[18
]}

Cilloni, Daniela ^{[19
]}

Hiwase, Devendra ^{[20
]}

Jurcic, Joseph G. ^{[21
]}

Krauter, Jurgen ^{[22
]}

Thomas, Xavier ^{[23
]}

Watts, Justin ^{[24
]}

Yang, Jay ^{[25
]}

Xin, Zihao ^{[26
]}

Sedkov, Alex ^{[26
]}

Guichard, Sylvie ^{[26
]}

Sweeney, Jennifer ^{[26
]}

Marzac, Christophe ^{[27
]}

Cortes, Jorge E. ^{[28
]}

Fenaux, Pierre ^{[29
]}

机构：

[1] Inst Gustave Roussy, Dept Haematol, Villejuif, France

[2] Princess Margaret Canc Ctr, Toronto, ON, Canada

[3] Inst Univ Canc Toulouse Oncopole, Paris, France

[4] Alfred Hosp, Dept Haematol, Melbourne, Australia

[5] Hosp Univ Politecn La Fe Valencia, Dept Hematol, Valencia, Spain

[6] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England

[7] Univ Bordeaux, Dept Hematol, Ctr HospUniv CHU Bordeaux, Bordeaux, France

[8] Paris XIII Univ, Hop Avicenne, AP HP, Bobigny, France

[9] IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy

[10] Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain

[11] PathWest Sir Charles Gairdner Hosp, Dept Haematol, Dept Hlth, Nedlands, WA, Australia

[12] Univ Calif Davis, Div Hematol & Oncol, Dept Internal Med, Davis, CA USA

[13] Univ Coll London Hosp, London, England

[14] Univ Coll Canc Inst, London, England

[15] St Antoine Univ Hosp, Dept Hematol, Paris, France

[16] CHU Nantes, Serv Hematol Clin, Nantes, France

[17] IDIBELL, Inst Catala Oncol, Hosp Duran & Reynals, Clin Hematol Dept, Barcelona, Spain

[18] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[19] Univ Turin, Dept Clin & Biol Sci, Turin, Italy

[20] Royal Adelaide Hosp, Dept Haematol, Adelaide, SA, Australia

[21] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Med Ctr, New York, NY USA

[22] Braunschweig Municipal Hosp, Dept Internal Med 3, Braunschweig, Germany

[23] Lyon Sud Univ Hosp, Hosp Civils Lyon, Dept Hematol, Pierre Benite, France

[24] Univ Miami, Dept Med, Leukemia Program, Sylvester Comprehens Canc Ctr, Miami, FL USA

[25] Karmanos Canc Inst, Dept Oncol, Detroit, MI USA

[26] Forma Therapeut Inc, Watertown, MA USA

[27] Univ Paris Saclay, Dept Biol pathol, Gustave Roussy, Villejuif, France

[28] Georgia Canc Ctr, Augusta, GA USA

[29] St Louis Hosp, Dept Haematol, Paris, France

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-144912

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2351

引用

页数：9

共 50 条

[21] FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study
Cortes, Jorge E.
Watts, Justin
Prebet, Thomas
Schiller, Gary J.
Lee, Sangmin
Yang, Jay
Wang, Eunice S.
Dinner, Shira
Ferrell, Paul Brent, Jr.
Donnellan, Will
Jonas, Brian A.
Wei, Andrew H.
Montesinos, Pau
Sangerman, Montserrat Arnan
Kelly, Patrick
Li, Ping
Sweeney, Jennifer
Watson, Courtney
Mohamed, Hesham
Baer, Maria R.
BLOOD, 2018, 132
[22] Response to Olutasidenib in Patients With Acute Myeloid Leukemia (AmL) Following Venetoclax Failure
Cortes, Jorge
Jonas, Brian A.
Di Trapani, Francois
Sheppard, Aaron
Watts, Justin M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S318 - S318
[23] Progress and strategies for patients with relapsed and refractory acute myeloid leukemia
Litzow, Mark R.
CURRENT OPINION IN HEMATOLOGY, 2007, 14 (02) : 130 - 137
[24] CURRENT TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Ferrara, F.
Isidori, A.
HAEMATOLOGICA, 2021, 106 (10) : 205 - 209
[25] Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Watts, Justin
Baer, Maria R.
Yang, Jay
Dinner, Shira
Lee, Sangmin
Seiter, Karen
Prebet, Thomas
Schiller, Gary J.
Ferrell, Paul Brent, Jr.
Dao, Kim-Hien
Kantarjian, Hagop M.
Kelly, Patrick
Li, Ping
Sweeney, Jennifer
Watson, Courtney
Mohamed, Hesham
Cortes, Jorge E.
BLOOD, 2018, 132
[26] PHASE 1 STUDY OF FT-2102, AN INHIBITOR OF MUTANT IDH1, IN PATIENTS WITH RELAPSED/REFRACTORY IDH1 MUTANT GLIOMAS: PRELIMINARY SAFETY AND CLINICAL ACTIVITY
De la Fuente, Macarena I.
Colman, Howard
Rosenthal, Mark
Van Tine, Brian A.
Fonkem, Ekokobe
Walbert, Tobias
Milhem, Mohammed
Lipford, Kate
Forsyth, Sanjeev
Guichard, Sylvie
Brevard, Julie
Mikhailov, Yelena
Thomson, Blythe
Monga, Varun
NEURO-ONCOLOGY, 2019, 21 : 25 - 25
[27] Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine
Cortes, Jorge E.
Wang, Eunice S.
Watts, Justin M.
Lee, Sangmin
Baer, Maria R.
Dao, Kim-Hien
Dinner, Shira
Yang, Jay
Donnellan, William B.
Schwarer, Anthony P.
Recher, Christian
Kelly, Patrick
Sweeney, Jennifer
Brevard, Julie
Henrick, Patrick
Forsyth, Sanjeev
Guichard, Sylvie
Mohamed, Hesham
Wei, Andrew H.
BLOOD, 2019, 134
[28] Ivosidenib to treat adult patients with relapsed or refractory acute myeloid leukemia
Pasquier, F.
Lecuit, M.
Broutin, S.
Saada, V
Jeanson, A.
Penard-Lacronique, V
de Botton, S.
DRUGS OF TODAY, 2020, 56 (01) : 21 - 35
[29] B Cell Deficiency in Patients with Relapsed and Refractory Acute Myeloid Leukemia
Meghali Goswami
Katherine E. Lindblad
Rahul Ramraj
Pradeep K. Dagur
Julie Thompson
J. Philip McCoy
Christopher S. Hourigan
Clinical Hematology International, 2020, 2 (3) : 125 - 128
[30] Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia
Weng, Guangyang
Zhang, Yu
Yu, Guopan
Luo, Tingyue
Yu, Sijian
Xu, Na
Sun, Zhiqiang
Lin, Dongjun
Deng, Lan
Liang, Xinquan
Xiao, Jie
Zhang, Hongyu
Guo, Ziwen
Shao, Ruoyang
Du, Xin
Jin, Hua
Liu, Qifa
JOURNAL OF INTERNAL MEDICINE, 2023, 293 (03) : 329 - 339

← 1 2 3 4 5 →